Kälble T, Möhring K, Ikinger U, Riedasch G, Staehler G
Urologische Abteilung Chirurgischen Universitätsklinik Heidelberg.
Urologe A. 1991 Mar;30(2):118-21.
In a prospective randomized trial intravesical prophylaxis for recurrence of superficial bladder cancer with BCG versus KLH was performed in 42 patients, 38 of whom were then evaluable. After a mean observation period of 20 +/- 7 months (8-32 months) 41.2% (7/17) of the patients in the KLH and 14.3% (3/21) of the patients in the BCG group developed recurrent bladder tumours. The recurrence rate according to EORTC was 1.95 in the KLH group versus 0.76 in the BCG group. Among the BCG treated patients, 60% (15/25) had cystitis and 28% (7/25) fever, whereas only 1 of 19 (5.3%) patients treated with KLH had cystitis. BCG is a highly effective prophylactic against recurrence of superficial bladder cancer. Intravesical instillation therapy with KLH has only a slight prophylactic effect if treatment is started 6 weeks postoperatively.
在一项前瞻性随机试验中，对42例患者进行了卡介苗（BCG）与钥孔血蓝蛋白（KLH）膀胱内预防浅表性膀胱癌复发的治疗，其中38例随后可进行评估。在平均20±7个月（8 - 32个月）的观察期后，KLH组41.2%（7/17）的患者和BCG组14.3%（3/21）的患者发生了复发性膀胱肿瘤。根据欧洲癌症研究与治疗组织（EORTC）的数据，KLH组的复发率为1.95，而BCG组为0.76。在接受BCG治疗的患者中，60%（15/25）出现膀胱炎，28%（7/25）出现发热，而在接受KLH治疗的19例患者中只有1例（5.3%）出现膀胱炎。BCG是预防浅表性膀胱癌复发的高效药物。如果在术后6周开始治疗，KLH膀胱内灌注疗法只有轻微的预防作用。
